Curis doeses first patient in Phase 1 trial of Dual PI3 Kinase, CUDC-907 Curis announced that the first patient has been treated in a Phase I clinical study of CUDC-907 in patients with relapsed or refractory lymphoma or multiple myeloma. CUDC-907 is an orally-administered first-in-class small molecule drug candidate that has been designed as a dual inhibitor of phosphatidylinositol-3-kinase and histone deacetylase. As a result of this clinical advance, Curis is entitled to receive an additional $350,000 in milestone payments under the terms of its agreement with The Leukemia and Lymphoma Society.
News For CRIS From The Last 14 Days
Check below for free stories on CRIS the last two weeks.